Achieving lipid goals in Europe: how large is the treatment gap?

Authors: Schwandt, Peter; Brady, Adrian JB

Source: Expert Review of Cardiovascular Therapy, Volume 2, Number 3, May 2004 , pp. 431-449(19)

Buy & download fulltext article:

Price: $73.00 plus tax (Refund Policy)

Abstract:

Despite the established benefits of decreasing low-density lipoprotein cholesterol levels in reducing morbidity and mortality from coronary heart disease, not all patients who would benefit from lipid-lowering therapy are being managed appropriately. An in-depth review of the literature (2000–2003) demonstrates that the ‘treatment gap’ varies across different clinical settings. Although the use of lipid-lowering agents has increased in recent years, there continues to be a widespread failure in the achievement of recommended lipid levels. A combination of the use of the most efficacious statins, together with intervention strategies to ensure that all eligible individuals receive appropriate treatment to achieve lipid goals, are important considerations in minimizing the burden of dyslipidemia in Europe.

Keywords: cholesterol; coronary heart disease; dyslipidemia; lipid-lowering therapy; statins; undertreatment; underuse

Document Type: Research article

DOI: http://dx.doi.org/10.1586/14779072.2.3.431

Publication date: 2004-05-01

More about this publication?

Expert Review of Cardiovascular Therapy provides expert commentary on the clinical applications of the new medicines, therapeutic agents and diagnostics in cardiovascular disease. Coverage inculdes drug therapy, heart disease, vascular disorders, hypertension, cholesterol in cardiovascular disease, heart disease, stroke, heart failure and cardiovascular surgery.
Editorial Board
Information for Authors
Submit a Paper
Subscribe to this Title
Information for Advertisers
Terms & Conditions
Information for Librarians
Free Trials
ingentaconnect is not responsible for the content or availability of external websites